Compare Sana Biotechnology Inc (SANA) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Unity Software Inc — how do they compare? Sana Biotechnology Inc trades at $2.9 (market cap $812.76M), while Unity Software Inc trades at $46.34 (market cap $20.20B). The key difference: Unity Software Inc is far larger — about 24.9× Sana Biotechnology Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Unity Software Inc for 50 Days on average.
| SANA | U | |
|---|---|---|
Market Cap | $812.76M | $20.20B |
Volume | 4,314,200 | 15,432,191 |
Sector | Health | Technology |
52-Week High | $5.92 | $49.47 |
52-Week Low | $2.68 | $17.13 |
Typical Hold Time | 23 Days | 50 Days |
Enterprise Value | $726.01M | $20.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
Unity Software (U) trades at $45.44, up 1.09% with bullish technical momentum and strong analyst support. The stock shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though profitability remains negative. Recent news highlights Meta VR partnership driving investor optimism, with technical indicators showing the stock testing resistance near $46.
Unity presents a growth story with improving cash flow and strategic partnerships, but faces execution risks amid persistent losses. With 82% analyst buy ratings and a $46.54 price target, Wall Street sees upside potential, though investors must weigh high valuation multiples against the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
